SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

How AI’s unseen revolution became a daily essential in just months

Social media’s double-edged sword: Israel’s war through the lens of Telegram and TikTok

Disillusionment from AI will lead to more productivity

Making Artificial Intelligence accessible to traditional institutions

Buzz

Most popular

Daily

Weekly

1

The next Wiz? Eon raises $77M at $750M valuation before product launch

2

How Intel's $108 billion buyback gambit backfired—a cautionary tale for tech giants

3

Nym raises $47 million for autonomous medical coding platform

4

Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive

5

The Gili Ra’anan model: Questions emerging from Cyberstarts' remarkable success

Sisram Medical

5 stories about Sisram Medical

מימין קאלואן פוסון ויליאם הו פוסום ליאור דיין מיסטר לואי

Fosun Whetted Our Appetite, Says Alma Lasers CEO

04.07.19|Golan Hazani

Fosun Pharma CEO Yifang Wu and Alma Lasers CEO Lior Dayan gave Calcalist their first joint interview since the Chinese conglomerate acquired the Israeli medical laser company in 2013

בכירי פוסון אלמא לייזרס וחברת נכסי קיסריה עם השק אלי כהן בטקס ב קיסריה

Fosun Pharma Inaugurates New Building for Israeli Subsidiary Sisram Medical

26.02.19|Golan Hazani

Fosun paid $240 million for a 95% stake in the Israeli cosmetic surgery in 2014, floating it on the Hong Kong Exchange in 2017

קיסריה קמפוס גרניט 2

Fosun Pharma Subsidiary Sisram Medical Leases 11,000-Square-Meter Building in Caesarea

10.12.18|Dotan Levy

The ten-year lease is estimated at $1.7 million (NIS 6.3 million) per year. China’s Fosun Pharma bought Sisram in 2014 for $240 million, renaming it from Alma Lasers

בורסת הונג קונג בורסה בורסות אסיה

Sisram Stock Price Down on Market Debut

19.09.17|Amarelle Wenkert

The Fosun Pharma subsidiary debuted on the Hong Kong Stock Exchange Tuesday

בורסת הונג קונג בורסה בורסות אסיה

Sisram Medical Seeks to Raise Up To $176 Million in Hong Kong IPO

10.09.17|Amarelle Wenkert

On September 5, the Fosun Pharma subsidiary submitted a prospectus to the Hong Kong Stock Exchange